Pricing Log in Create free account

PMGC Holdings Inc. (ELAB) vs Karyopharm Therapeutics Inc. (KPTI)

PMGC Holdings Inc. and Karyopharm Therapeutics Inc. are both Biotechnology companies. PMGC Holdings Inc. and Karyopharm Therapeutics Inc. are of similar size ($1.4M and $1.3M). Karyopharm Therapeutics Inc. grew revenue faster over the last twelve months: 6.81% against 5.41%. Karyopharm Therapeutics Inc. has the higher net margin (−153.3% vs −523.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Karyopharm Therapeutics Inc. leads on 10 and PMGC Holdings Inc. on 5.

Valuation

Metric ELAB KPTI Biotechnology median
P/E n/m n/m 10.60
P/S 0.31 0.01 9.40
P/B 0.05 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 1.58 n/m 0.66
EV/Sales (6.87) 1.27 9.02
Earnings yield (127,538.28%) (25,680.00%) (32.88%)
Free cash flow yield (1,131.30%) (4,526.16%) (23.13%)

Profitability

Metric ELAB KPTI Biotechnology median
Gross margin 31.08% 95.89% 68.51%
Operating margin (458.63%) (56.17%) 0.00%
Net margin (522.99%) (153.28%) 0.00%
Free cash flow margin (348.69%) (44.57%) 0.00%
Return on equity (104.60%) 78.98% (51.96%)
Return on assets (58.71%) (207.90%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ELAB KPTI Biotechnology median
Revenue growth (TTM) 5.41% 6.81% 6.76%
EPS growth (last fiscal year) 94.22% (28.07%) 29.88%
Revenue growth, 5-year CAGR — 6.21% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ELAB KPTI Biotechnology median
Debt to equity 0.02 (0.76) 0.00
Current ratio 1.36 0.79 4.97
Net debt to EBITDA 0.87 (2.03) 1.01

Dividend

Metric ELAB KPTI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ELAB KPTI Biotechnology median
Market cap 1.33m 1.36m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack